Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
5.75    -0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread: 0.10 (1.754%)
Market Cap: £61.50m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Form 8.5 (EPT/RI) - Shield Therapeutics Plc

30 May 2023 12:00

RNS Number : 0403B
Peel Hunt LLP
30 May 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shield Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Shield Therapeutics Plc

(d) Date dealing undertaken:

26 May 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Purchase

38,336

6.63 GBx

6.63 GBx

Ordinary Shares

Sale

163,853

6.72 GBx

6.70 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

Date of disclosure:

30 May 2023

 

Contact name:

Alexandra Forner

Telephone number:

0207 847 4740

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERBGGDULSXDGXG
Date   Source Headline
29th May 20269:11 amRNSTotal Voting Rights
5th May 20267:00 amRNSGrant of Share Options
1st May 20267:00 amRNSQ1 2026 Trading Update
30th Apr 20267:01 amRNSTotal Voting Rights
27th Apr 20267:00 amRNSEnrollment in Phase II Clinical Trial for ACCRUFeR
9th Apr 202612:30 pmRNSAudited results for year ended 31 December 2025
1st Apr 20269:22 amRNS-RPublication of Report, Reinforcing FDA Approval
31st Mar 20267:03 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSEMA approves extension - to include adolescents
3rd Mar 20267:00 amRNSChinese NMPA Accepts MAA Submission for ACCRUFeR®
27th Feb 20267:00 amRNSTotal Voting Rights
9th Feb 20267:00 amRNSFDA Grants additional Exclusivity for ACCRUFeR
30th Jan 20267:05 amRNSTotal Voting Rights
30th Jan 20267:00 amRNSApproval for ACCRUFeR in China expected in Q1 2026
21st Jan 20267:00 amRNSQ4 2025 Trading Update
2nd Jan 202611:06 amRNSBlock listing 6 Monthly Return
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
18th Dec 20257:13 amRNSBlock Listing Application
11th Dec 20257:00 amRNS-RShield Wins Gold at Titan Branding Awards
3rd Dec 20257:04 amRNSAmends Senior Secured Debt Financing
14th Nov 20257:03 amRNSInitiation of a Phase II Clinical Trial in Japan
11th Nov 20257:00 amRNSACCRUFeR Pediatric PK Results to be Presented
7th Nov 20257:03 amRNSACCRUFeR receives Authorisation by Korean Ministry
23rd Oct 20257:00 amRNSQ3 2025 Trading Update
14th Oct 20253:01 pmRNSGrant of Share Options to Chief Executive Officer
1st Oct 20258:00 amRNSTotal Voting Rights
1st Oct 20257:02 amRNSPositive efficacy and tolerance in pediatric trial
15th Sep 20257:00 amRNS£1.5 million placing supporting growth of ACCRUFeR
4th Sep 20257:03 amRNSACCRUFeR® assigned Priority Review in US by FDA
3rd Sep 20252:17 pmRNSInterim results for the six months ended 30 Jun 25
27th Aug 20257:13 amRNSData published -European Journal of Heart Failure
21st Aug 202512:06 pmRNSInterim results for the six months ended 30 Jun 25
23rd Jul 20257:00 amRNSQ2 2025 Trading Update
22nd May 20255:06 pmRNSResult of AGM
24th Apr 20257:06 amRNSAudited results for the year ended 31 Dec 2024
22nd Apr 20257:01 amRNSLicence Agreement in Japan for ACCRUFeR®
17th Apr 202511:23 amRNSQ1 2025 Trading Update
11th Mar 20257:00 amRNSACCRUFeR® launched in Canada
13th Feb 20254:15 pmRNSPDMR Transaction Notification
13th Feb 20257:00 amRNSGrant of Share Options
5th Feb 20257:00 amRNSUnaudited full year trading update
27th Jan 20257:00 amRNSAnders Lundstrom appointed CEO
24th Dec 202411:25 amRNSResult of General Meeting & Total Voting Rights
23rd Dec 20247:00 amRNSResults of RetailBook Offer
6th Dec 202411:31 amRNSRetailBook Offer
6th Dec 202411:30 amRNSSubscription by AOP Health to raise US$10 million
21st Nov 20247:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.